LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) is investigating potential claims on behalf of investors of XBiotech, Inc. (“XBiotech” or the “Company”) (NASDAQ: XBIT) concerning the Company’s and its officers’ possible violations of federal securities laws.
On November 23, 2015, XBiotech issued a press release announcing that data associated with one of its Phase III studies was compromised due to fewer numbers of per protocol patients available for primary endpoint evaluation. The Company found that (1) 25 patients dropped off study prior to receiving any dosing with drug or placebo, (2) 14 patients erroneously received either placebo or study drug, and (3) 33 patients completed the study but failed to receive scheduled DEXA scans, properly complete EORTC evaluation, or both. In total, the combined irregularities compromised data from 72 patients in the study.
On this news, XBiotech shares fell more than 30% during intra-day trading on November 24, 2015.
If you purchased XBiotech securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.